IBDEI029 ; ; 18-NOV-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 18, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,2493,2)
 ;;=^267538
 ;;^UTILITY(U,$J,358.3,2494,0)
 ;;=205.32^^26^185^33
 ;;^UTILITY(U,$J,358.3,2494,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2494,1,1,0)
 ;;=1^205.32
 ;;^UTILITY(U,$J,358.3,2494,1,8,0)
 ;;=8^Myeloid Sarcoma in Relapse
 ;;^UTILITY(U,$J,358.3,2494,2)
 ;;=^336473
 ;;^UTILITY(U,$J,358.3,2495,0)
 ;;=205.80^^26^185^44
 ;;^UTILITY(U,$J,358.3,2495,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2495,1,1,0)
 ;;=1^205.80
 ;;^UTILITY(U,$J,358.3,2495,1,8,0)
 ;;=8^Oth Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,2495,2)
 ;;=^336859
 ;;^UTILITY(U,$J,358.3,2496,0)
 ;;=205.81^^26^185^43
 ;;^UTILITY(U,$J,358.3,2496,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2496,1,1,0)
 ;;=1^205.81
 ;;^UTILITY(U,$J,358.3,2496,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,2496,2)
 ;;=^267540
 ;;^UTILITY(U,$J,358.3,2497,0)
 ;;=205.82^^26^185^42
 ;;^UTILITY(U,$J,358.3,2497,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2497,1,1,0)
 ;;=1^205.82
 ;;^UTILITY(U,$J,358.3,2497,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,2497,2)
 ;;=^336474
 ;;^UTILITY(U,$J,358.3,2498,0)
 ;;=205.90^^26^185^65
 ;;^UTILITY(U,$J,358.3,2498,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2498,1,1,0)
 ;;=1^205.90
 ;;^UTILITY(U,$J,358.3,2498,1,8,0)
 ;;=8^Unspec Myeloid Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,2498,2)
 ;;=^336860
 ;;^UTILITY(U,$J,358.3,2499,0)
 ;;=205.91^^26^185^64
 ;;^UTILITY(U,$J,358.3,2499,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2499,1,1,0)
 ;;=1^205.91
 ;;^UTILITY(U,$J,358.3,2499,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Remission
 ;;^UTILITY(U,$J,358.3,2499,2)
 ;;=^267542
 ;;^UTILITY(U,$J,358.3,2500,0)
 ;;=205.92^^26^185^63
 ;;^UTILITY(U,$J,358.3,2500,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2500,1,1,0)
 ;;=1^205.92
 ;;^UTILITY(U,$J,358.3,2500,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,2500,2)
 ;;=^336475
 ;;^UTILITY(U,$J,358.3,2501,0)
 ;;=206.00^^26^185^6
 ;;^UTILITY(U,$J,358.3,2501,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2501,1,1,0)
 ;;=1^206.00
 ;;^UTILITY(U,$J,358.3,2501,1,8,0)
 ;;=8^Acute Monocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,2501,2)
 ;;=^336861
 ;;^UTILITY(U,$J,358.3,2502,0)
 ;;=206.01^^26^185^5
 ;;^UTILITY(U,$J,358.3,2502,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2502,1,1,0)
 ;;=1^206.01
 ;;^UTILITY(U,$J,358.3,2502,1,8,0)
 ;;=8^Acute Monocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,2502,2)
 ;;=^267544
 ;;^UTILITY(U,$J,358.3,2503,0)
 ;;=206.02^^26^185^4
 ;;^UTILITY(U,$J,358.3,2503,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2503,1,1,0)
 ;;=1^206.02
 ;;^UTILITY(U,$J,358.3,2503,1,8,0)
 ;;=8^Acute Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,2503,2)
 ;;=^336476
 ;;^UTILITY(U,$J,358.3,2504,0)
 ;;=206.10^^26^185^15
 ;;^UTILITY(U,$J,358.3,2504,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2504,1,1,0)
 ;;=1^206.10
 ;;^UTILITY(U,$J,358.3,2504,1,8,0)
 ;;=8^Chr Monocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,2504,2)
 ;;=^336862
 ;;^UTILITY(U,$J,358.3,2505,0)
 ;;=206.11^^26^185^14
 ;;^UTILITY(U,$J,358.3,2505,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2505,1,1,0)
 ;;=1^206.11
 ;;^UTILITY(U,$J,358.3,2505,1,8,0)
 ;;=8^Chr Monocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,2505,2)
 ;;=^267546
 ;;^UTILITY(U,$J,358.3,2506,0)
 ;;=206.12^^26^185^13
 ;;^UTILITY(U,$J,358.3,2506,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2506,1,1,0)
 ;;=1^206.12
 ;;^UTILITY(U,$J,358.3,2506,1,8,0)
 ;;=8^Chr Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,2506,2)
 ;;=^336477
 ;;^UTILITY(U,$J,358.3,2507,0)
 ;;=206.20^^26^185^55
 ;;^UTILITY(U,$J,358.3,2507,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2507,1,1,0)
 ;;=1^206.20
 ;;^UTILITY(U,$J,358.3,2507,1,8,0)
 ;;=8^Subacute Monocytic Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,2507,2)
 ;;=^336863
 ;;^UTILITY(U,$J,358.3,2508,0)
 ;;=206.21^^26^185^54
 ;;^UTILITY(U,$J,358.3,2508,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2508,1,1,0)
 ;;=1^206.21
 ;;^UTILITY(U,$J,358.3,2508,1,8,0)
 ;;=8^Subacute Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,2508,2)
 ;;=^267548
 ;;^UTILITY(U,$J,358.3,2509,0)
 ;;=206.22^^26^185^56
 ;;^UTILITY(U,$J,358.3,2509,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2509,1,1,0)
 ;;=1^206.22
 ;;^UTILITY(U,$J,358.3,2509,1,8,0)
 ;;=8^Subacute Monocytic Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,2509,2)
 ;;=^336478
 ;;^UTILITY(U,$J,358.3,2510,0)
 ;;=206.80^^26^185^41
 ;;^UTILITY(U,$J,358.3,2510,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2510,1,1,0)
 ;;=1^206.80
 ;;^UTILITY(U,$J,358.3,2510,1,8,0)
 ;;=8^Oth Monocytic Leuk w/ Remission
 ;;^UTILITY(U,$J,358.3,2510,2)
 ;;=^336864
 ;;^UTILITY(U,$J,358.3,2511,0)
 ;;=206.81^^26^185^40
 ;;^UTILITY(U,$J,358.3,2511,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2511,1,1,0)
 ;;=1^206.81
 ;;^UTILITY(U,$J,358.3,2511,1,8,0)
 ;;=8^Oth Monocytic Leuk w/ Remiss
 ;;^UTILITY(U,$J,358.3,2511,2)
 ;;=^267551
 ;;^UTILITY(U,$J,358.3,2512,0)
 ;;=206.82^^26^185^39
 ;;^UTILITY(U,$J,358.3,2512,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2512,1,1,0)
 ;;=1^206.82
 ;;^UTILITY(U,$J,358.3,2512,1,8,0)
 ;;=8^Oth Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,2512,2)
 ;;=^336479
 ;;^UTILITY(U,$J,358.3,2513,0)
 ;;=206.90^^26^185^62
 ;;^UTILITY(U,$J,358.3,2513,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2513,1,1,0)
 ;;=1^206.90
 ;;^UTILITY(U,$J,358.3,2513,1,8,0)
 ;;=8^Unspec Monocytic Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,2513,2)
 ;;=^336865
 ;;^UTILITY(U,$J,358.3,2514,0)
 ;;=206.91^^26^185^61
 ;;^UTILITY(U,$J,358.3,2514,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2514,1,1,0)
 ;;=1^206.91
 ;;^UTILITY(U,$J,358.3,2514,1,8,0)
 ;;=8^Unspec Monocytic Leuk in Remiss
 ;;^UTILITY(U,$J,358.3,2514,2)
 ;;=^267554
 ;;^UTILITY(U,$J,358.3,2515,0)
 ;;=206.92^^26^185^60
 ;;^UTILITY(U,$J,358.3,2515,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2515,1,1,0)
 ;;=1^206.92
 ;;^UTILITY(U,$J,358.3,2515,1,8,0)
 ;;=8^Unspec Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,2515,2)
 ;;=^336480
 ;;^UTILITY(U,$J,358.3,2516,0)
 ;;=207.00^^26^185^3
 ;;^UTILITY(U,$J,358.3,2516,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2516,1,1,0)
 ;;=1^207.00
 ;;^UTILITY(U,$J,358.3,2516,1,8,0)
 ;;=8^AC Eryth & Erythroleuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,2516,2)
 ;;=^336866
 ;;^UTILITY(U,$J,358.3,2517,0)
 ;;=207.01^^26^185^1
 ;;^UTILITY(U,$J,358.3,2517,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2517,1,1,0)
 ;;=1^207.01
 ;;^UTILITY(U,$J,358.3,2517,1,8,0)
 ;;=8^AC Eryth & Erythroleuk in Relapse
 ;;^UTILITY(U,$J,358.3,2517,2)
 ;;=^267556
 ;;^UTILITY(U,$J,358.3,2518,0)
 ;;=207.02^^26^185^2
 ;;^UTILITY(U,$J,358.3,2518,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2518,1,1,0)
 ;;=1^207.02
 ;;^UTILITY(U,$J,358.3,2518,1,8,0)
 ;;=8^AC Eryth & Erythroleuk in Relapse
 ;;^UTILITY(U,$J,358.3,2518,2)
 ;;=^336481
 ;;^UTILITY(U,$J,358.3,2519,0)
 ;;=207.10^^26^185^9
 ;;^UTILITY(U,$J,358.3,2519,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2519,1,1,0)
 ;;=1^207.10
 ;;^UTILITY(U,$J,358.3,2519,1,8,0)
 ;;=8^Chr Erythremia w/o Remission
 ;;^UTILITY(U,$J,358.3,2519,2)
 ;;=^336867
 ;;^UTILITY(U,$J,358.3,2520,0)
 ;;=207.11^^26^185^8
 ;;^UTILITY(U,$J,358.3,2520,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2520,1,1,0)
 ;;=1^207.11
 ;;^UTILITY(U,$J,358.3,2520,1,8,0)
 ;;=8^Chr Erythremia in Remission
 ;;^UTILITY(U,$J,358.3,2520,2)
 ;;=^267558
 ;;^UTILITY(U,$J,358.3,2521,0)
 ;;=207.12^^26^185^7
 ;;^UTILITY(U,$J,358.3,2521,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2521,1,1,0)
 ;;=1^207.12
 ;;^UTILITY(U,$J,358.3,2521,1,8,0)
 ;;=8^Chr Erythremia in Relapse
 ;;^UTILITY(U,$J,358.3,2521,2)
 ;;=^336482
 ;;^UTILITY(U,$J,358.3,2522,0)
 ;;=207.20^^26^185^28
 ;;^UTILITY(U,$J,358.3,2522,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2522,1,1,0)
 ;;=1^207.20
 ;;^UTILITY(U,$J,358.3,2522,1,8,0)
 ;;=8^Megakaryocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,2522,2)
 ;;=^336868
 ;;^UTILITY(U,$J,358.3,2523,0)
 ;;=207.21^^26^185^27
 ;;^UTILITY(U,$J,358.3,2523,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2523,1,1,0)
 ;;=1^207.21
 ;;^UTILITY(U,$J,358.3,2523,1,8,0)
 ;;=8^Megakaryocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,2523,2)
 ;;=^267560
 ;;^UTILITY(U,$J,358.3,2524,0)
 ;;=207.22^^26^185^26
 ;;^UTILITY(U,$J,358.3,2524,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2524,1,1,0)
 ;;=1^207.22
 ;;^UTILITY(U,$J,358.3,2524,1,8,0)
 ;;=8^Megakaryocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,2524,2)
 ;;=^336483
 ;;^UTILITY(U,$J,358.3,2525,0)
 ;;=207.80^^26^185^47
 ;;^UTILITY(U,$J,358.3,2525,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2525,1,1,0)
 ;;=1^207.80
 ;;^UTILITY(U,$J,358.3,2525,1,8,0)
 ;;=8^Oth Spec Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,2525,2)
 ;;=^336869
 ;;^UTILITY(U,$J,358.3,2526,0)
 ;;=207.81^^26^185^46
 ;;^UTILITY(U,$J,358.3,2526,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2526,1,1,0)
 ;;=1^207.81
 ;;^UTILITY(U,$J,358.3,2526,1,8,0)
 ;;=8^Oth Spec Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,2526,2)
 ;;=^267562
 ;;^UTILITY(U,$J,358.3,2527,0)
 ;;=207.82^^26^185^45
 ;;^UTILITY(U,$J,358.3,2527,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2527,1,1,0)
 ;;=1^207.82
 ;;^UTILITY(U,$J,358.3,2527,1,8,0)
 ;;=8^Oth Spec Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,2527,2)
 ;;=^336484
 ;;^UTILITY(U,$J,358.3,2528,0)
 ;;=208.00^^26^185^21
 ;;^UTILITY(U,$J,358.3,2528,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2528,1,1,0)
 ;;=1^208.00
 ;;^UTILITY(U,$J,358.3,2528,1,8,0)
 ;;=8^Leukemia Unspec w/o Remission
 ;;^UTILITY(U,$J,358.3,2528,2)
 ;;=^336870
 ;;^UTILITY(U,$J,358.3,2529,0)
 ;;=208.01^^26^185^20
 ;;^UTILITY(U,$J,358.3,2529,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2529,1,1,0)
 ;;=1^208.01
 ;;^UTILITY(U,$J,358.3,2529,1,8,0)
 ;;=8^Leukemia Unspec in Remission
 ;;^UTILITY(U,$J,358.3,2529,2)
 ;;=^267566
 ;;^UTILITY(U,$J,358.3,2530,0)
 ;;=208.02^^26^185^19
 ;;^UTILITY(U,$J,358.3,2530,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2530,1,1,0)
 ;;=1^208.02
